ARTICLE | Clinical News
Nimotuzumab: Completed Phase II enrollment
February 21, 2011 8:00 AM UTC
YM BioSciences disclosed in its fiscal 2Q11 earnings that partner Daiichi Sankyo completed enrollment in a Phase II trial evaluating nimotuzumab in combination with radiation therapy, cisplatin and vi...